Research graph
References from Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(20)30183-5
10.1016/s0140-6736(20)30183-5 · External reference
10.1038/s41564-020-0695-z
10.1038/s41564-020-0695-z · External reference
10.1016/j.meegid.2020.104327
10.1016/j.meegid.2020.104327 · External reference
Protein Data Bank: the single global archive for 3D macromolecular structure data
10.1093/nar/gky949 · 2019 · External reference
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
10.1038/s41421-020-0153-3 · 2020 · External reference
10.1038/s41586-020-2286-9
10.1038/s41586-020-2286-9 · External reference
SPRITE and ASSAM: web servers for side chain 3D-motif searching in protein structures
10.1093/nar/gks401 · 2012 · External reference
10.1093/nar/gkt431
10.1093/nar/gkt431 · External reference
Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning
10.1093/nar/gkz391 · 2019 · External reference
10.1016/j.csbj.2020.04.004
10.1016/j.csbj.2020.04.004 · External reference
Drug promiscuity in PDB: protein binding site similarity is key
2013 · External reference
10.1093/bioinformatics/btq003
10.1093/bioinformatics/btq003 · External reference
SPRITE and ASSAM: web servers for side chain 3D-motif searching in protein structures
10.1093/nar/gks401 · 2012 · External reference
10.1002/jcc.21334
10.1002/jcc.21334 · External reference
10.1002/jcc.20084
10.1002/jcc.20084 · External reference
UniProtKB/Swiss-Prot
2007 · External reference
Trial Reporting in ClinicalTrials.gov — the final rule
10.1056/nejmsr1611785 · 2016 · External reference
10.21203/rs.3.rs-28113/v1
10.21203/rs.3.rs-28113/v1 · External reference
Computational view toward the inhibition of SARS-CoV-2 spike glycoprotein and the 3CL protease
10.3390/computation8020053 · 2020 · External reference
10.26434/chemrxiv.12279671.v1
10.26434/chemrxiv.12279671.v1 · External reference
10.26434/chemrxiv.12355937.v1
10.26434/chemrxiv.12355937.v1 · External reference
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
10.1038/d41573-020-00016-0 · 2020 · External reference
10.1016/j.bbrc.2004.04.083
10.1016/j.bbrc.2004.04.083 · External reference
10.1038/nrd.2015.37
10.1038/nrd.2015.37 · External reference
10.1074/jbc.m114.577353
10.1074/jbc.m114.577353 · External reference
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
10.1038/s41467-019-10280-3 · 2019 · External reference
Indomethacin and resveratrol as potential treatment adjuncts for SARS‐CoV‐2/COVID‐19
10.1111/ijcp.13535 · 2020 · External reference
10.1073/pnas.052713799
10.1073/pnas.052713799 · External reference
10.21203/rs.3.rs-21833/v1
10.21203/rs.3.rs-21833/v1 · External reference
The conserved coronavirus macrodomain promotes virulence and suppresses the innate immune response during severe acute respiratory syndrome coronavirus infection
2016 · External reference
Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects
10.1186/s40360-017-0128-7 · 2017 · External reference
The lysosomal protein saposin B binds chloroquine
10.1002/cmdc.201500494 · 2016 · External reference
10.1016/j.ijpara.2003.09.011
10.1016/j.ijpara.2003.09.011 · External reference
4-Acyl pyrroles: mimicking acetylated lysines in histone code reading
10.1002/anie.201307652 · 2013 · External reference
10.1515/hsz-2018-0342
10.1515/hsz-2018-0342 · External reference
PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery: PDE5 inhibitors
10.1111/bph.14205 · 2018 · External reference
Unresolved reference
External reference
Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and Implications in Drug Development
10.2174/092986709789057635 · 2009 · External reference
10.1016/j.str.2008.09.007
10.1016/j.str.2008.09.007 · External reference
Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs
2015 · External reference
10.20944/preprints202003.0457.v1
10.20944/preprints202003.0457.v1 · External reference
10.1091/mbc.e16-01-0012
10.1091/mbc.e16-01-0012 · External reference
Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII
10.1016/j.ijbiomac.2018.07.164 · 2018 · External reference
10.1016/j.febslet.2005.05.030
10.1016/j.febslet.2005.05.030 · External reference
Different origin of adipogenic stem cells influences the response to antiretroviral drugs
10.1016/j.yexcr.2015.07.031 · 2015 · External reference
10.1371/journal.pone.0063118
10.1371/journal.pone.0063118 · External reference
Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies
2012 · External reference
10.1128/mcb.00293-12
10.1128/mcb.00293-12 · External reference
10.1261/rna.2549411
10.1261/rna.2549411 · External reference
10.1111/j.1348-0421.2011.00424.x
10.1111/j.1348-0421.2011.00424.x · External reference
Influenza virus infection causes neutrophil dysfunction through reduced G-CSF production and an increased risk of secondary bacteria infection in the lung
10.1016/j.virol.2016.08.025 · 2016 · External reference
Perturbation of intracellular cholesterol and fatty acid homeostasis during flavivirus infections
10.3389/fimmu.2018.01276 · 2018 · External reference
Neurologic complications of HIV-1 infection and its treatment in the Era of antiretroviral therapy
2012 · External reference
A comparison of neurodegeneration linked with neuroinflammation in different brain areas of rats after intracerebroventricular colchicine injection
10.3109/1547691x.2015.1030804 · 2016 · External reference
Risk of stroke associated with nonsteroidal anti-inflammatory drugs
2014 · External reference
A case of parkinsonism worsened by losartan: a probable new adverse effect: Letters to the Editor
10.1002/mds.21945 · 2008 · External reference
Proteomic investigations of human HERC2 mutants: Insights into the pathobiology of a neurodevelopmental disorder
10.1016/j.bbrc.2019.02.149 · 2019 · External reference
10.1155/2012/860923
10.1155/2012/860923 · External reference
10.1128/jvi.00195-11
10.1128/jvi.00195-11 · External reference
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
10.1038/ncomms12849 · 2016 · External reference
Evidence that the angiotensin IV (AT 4) receptor is the enzyme insulin-regulated aminopeptidase
10.1074/jbc.c100512200 · 2001 · External reference
10.1371/journal.ppat.0020007
10.1371/journal.ppat.0020007 · External reference
10.1093/brain/awz123
10.1093/brain/awz123 · External reference
10.1021/acs.jmedchem.9b00058
10.1021/acs.jmedchem.9b00058 · External reference
10.1159/000480652
10.1159/000480652 · External reference
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms
10.1016/j.autrev.2020.102572 · 2020 · External reference
10.3389/fchem.2018.00315
10.3389/fchem.2018.00315 · External reference
10.1517/13543784.9.2.371
10.1517/13543784.9.2.371 · External reference
Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review
10.1007/s40261-018-0656-y · 2018 · External reference
Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine
10.1111/j.1365-4362.1981.tb05295.x · 1981 · External reference
Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial
10.1002/j.1939-4640.2002.tb02332.x · 2002 · External reference
Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction
10.1517/14656566.6.1.75 · 2005 · External reference
10.1177/2040620713480155
10.1177/2040620713480155 · External reference
Lenalidomide and thalidomide: mechanisms of action—similarities and differences
10.1053/j.seminhematol.2005.10.001 · 2005 · External reference
10.2133/dmpk.dmpk-13-rv-119
10.2133/dmpk.dmpk-13-rv-119 · External reference
10.1056/nejm197504172921607
10.1056/nejm197504172921607 · External reference
Adverse drug reaction to methotrexate: pharmacogenetic origin
2006 · External reference
10.1093/bioinformatics/btaa224
10.1093/bioinformatics/btaa224 · External reference
10.1021/nn405674m
10.1021/nn405674m · External reference
